论文信息 - Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies - 字舞流文

Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

F. Janku | A. Naing | S. Piha-Paul | A. Tsimberidou | J. Roszik | S. Fu | Ying Yuan | Yunfang Jiang | Shizhen Zhang | Shubham Pant | David S Hong | V. Subbiah | Niamh Coleman | Funda Meric-Bernstam | J. Rodón | Ecaterina E. Dumbrava | Ming Sun | Juhee Song